Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month Low - Here's Why

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $26.64 and last traded at $27.50, with a volume of 205614 shares traded. The stock had previously closed at $28.14.

Analyst Upgrades and Downgrades

Several research firms recently commented on COLL. StockNews.com raised shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of "Buy" and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The business's fifty day moving average price is $29.14 and its 200-day moving average price is $31.60. The stock has a market cap of $845.07 million, a PE ratio of 11.34 and a beta of 0.76.

Remove Ads

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company's stock, valued at approximately $4,959,032.46. This trade represents a 5.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 81,693 shares of company stock valued at $2,334,994. 3.98% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Large investors have recently made changes to their positions in the business. Invesco Ltd. raised its stake in shares of Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares during the period. Principal Financial Group Inc. lifted its stake in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after acquiring an additional 64,958 shares during the period. Renaissance Technologies LLC raised its stake in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock worth $47,603,000 after buying an additional 5,480 shares in the last quarter. Geode Capital Management LLC boosted its position in Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after purchasing an additional 5,464 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Collegium Pharmaceutical by 5.6% in the fourth quarter. Northern Trust Corp now owns 385,157 shares of the specialty pharmaceutical company's stock worth $11,035,000 after purchasing an additional 20,490 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.